CLAIRE EXUM: Open Payments
NPI 1053952648 · KANSAS CITY, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$985 in 48 payments from 16 companies in 2025. Trend: 2023 $1,310 · 2024 $1,408 · 2025 $985
Food & beverage: $937Education: $48
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 14 | $177 |
| AstraZeneca Pharmaceuticals LP | 6 | $172 |
| GlaxoSmithKline, LLC. | 5 | $113 |
| Novo Nordisk Inc | 5 | $107 |
| Madrigal Pharmaceuticals | 2 | $58 |
| Corcept Therapeutics | 3 | $50 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| Aimmune Therapeutics, Inc. | 2 | $42 |
| Merck Sharp & Dohme LLC | 1 | $41 |
| Amgen Inc. | 2 | $39 |
Products named: ELIQUIS, AIRSUPRA, Ozempic, TRELEGY ELLIPTA, BREZTRI, REZDIFFRA, Korlym, REXULTI.
Industry payments across KS — which companies pay providers there.
